Ka papa inoa o nā luna kiʻekiʻe ma Swiss Nā ʻoihana lāʻau lapaʻau i hoʻokaʻawale ʻia ma muli o ka huina kālā o ka makahiki i hala. ʻO Roche ka nui loa ʻOihana Kamepiula ma Switzerland me ka loaʻa ʻana o $ 66 Billion i ka makahiki i hala a ukali ʻia e Novartis a me Vifor.
Roche – Nui loa ʻoihana lāʻau lapaʻau ma Swiss: I loko o ka mōʻaukala 125-makahiki, ua ulu ʻo Roche i kekahi o nā ʻoihana biotech nui loa o ka honua, a he alakaʻi alakaʻi i nā diagnostics in-vitro a me kahi mea hoʻolako honua o nā hoʻonā hoʻololi hou i nā wahi maʻi nui.
Ka papa inoa o nā ʻoihana Lapaʻau Kiʻekiʻe ma Swiss
No laila eia ka papa inoa o nā mea kiʻekiʻe ma Swiss mea lāʻau lapaʻau ʻO nā hui ma ka huina o nā Kūʻai (Revenue).
S.NO | Description | Ka hōʻiliʻili kālā | limahana | ʻAiʻe-i-Equity ratio | Hoʻi i ka Pono | Hōʻailona Kūʻai |
1 | POHAKU | $ 65,980 Million | 101465 | 0.4 | 40.4 | RO |
2 | NOVARTIS | $ 51,668 Million | 105794 | 0.6 | 17.3 | NOVN |
3 | VIFOR | $ 1,930 Million | 2600 | 0.2 | 5.9 | VIFN |
4 | SIEGFRIED | $ 956 Million | 2500 | 0.9 | 13.9 | SFZN |
5 | BACHEM | $ 455 Million | 1529 | 0.3 | 21.3 | BANB |
6 | BASILEA | $ 144 Million | 150 | -2.9 | BSLN | |
7 | IDORSIA | $ 81 Million | 5.5 | -237.9 | MANAʻO | |
8 | COSMO PHARM | $ 74 Million | 265 | 0.5 | -2.8 | COPN |
9 | SANTERA | $ 17 Million | 91 | 5.2 | -1316.2 | SAN |
10 | SPEXIS N | $ 16 Million | 52 | -1.6 | -347.9 | SPEX |
11 | EVOLVA N | $ 9 Million | 65 | 0.1 | -29.1 | EVE |
12 | ʻO NEWRON PHARMA N | $ 6 Million | 3.1 | -110.5 | NWN | |
13 | ADDEX N | $ 4 Million | 27 | 0.0 | -89.8 | ADXN |
ʻO Novartis - ʻO ka hui ʻelua Swiss Pharma Company
Ua hana ʻia ʻo Novartis ma 1996 ma o ka hui ʻana o Ciba-Geigy a me Sandoz. ʻO Novartis a me kāna mau ʻoihana mua i ʻike i nā aʻa ma mua o 250 mau makahiki, me ka mōʻaukala waiwai o ka hoʻomohala ʻana i nā huahana hou.
Ke hana hou nei ʻo Novartis i ka lāʻau lapaʻau e hoʻomaikaʻi a hoʻonui i ke ola o nā kānaka. Ma ke ʻano he hui lāʻau lapaʻau koʻikoʻi o ka honua, hoʻohana ka hui i nā ʻepekema hou a me nā ʻenehana kikohoʻe e hana i nā lāʻau lapaʻau hoʻololi i nā wahi o ka pono olakino. I kā mākou ʻimi e ʻimi i nā lāʻau lapaʻau hou, kū mau ka hui ma waena o ka honua ʻoihana kiʻekiʻe hoʻokomo kālā i ka noiʻi a me ka hoʻomohala ʻana.
Loaʻa nā huahana Novartis ma kahi o 800 miliona mau kānaka a puni ka honua a ke ʻimi nei mākou i nā ala hou e hoʻonui i ke komo ʻana i kā mākou lapaʻau hou. Ma kahi o 110,000 poʻe o nā lāhui ʻoi aku ma mua o 140 e hana ana ma Novartis a puni ka honua.
ʻO Vifor Pharma
ʻO Vifor Pharma Group kahi hui lāʻau lapaʻau honua. Manaʻo ia e lilo i alakaʻi honua i ka hao a me ka nephrology me ka nānā ʻana i nā maʻi maʻamau. ʻO ka hui ka hoa koho no nā lāʻau lapaʻau a me nā mea hoʻonā hoʻomanawanui.
Hoʻoikaika ʻo Vifor Pharma Group e kōkua i nā poʻe maʻi a puni ka honua me nā maʻi koʻikoʻi a me nā maʻi maʻi e alakaʻi i nā ola maikaʻi aʻe.
Bachem
Ua hoʻokumu ʻia ʻo Bachem ma 1971 e Peter Grogg e like me Bachem Feinchemikalien AG me ʻelua mau limahana ma Liestal kokoke i Basel me ka nānā ʻana i ka peptide synthesis. Ma 1977, neʻe ʻo Bachem i Bubendorf me ʻewalu mau limahana a ma 1978 i hana i nā peptides no ka hoʻohana ʻana i ka lāʻau lapaʻau ma lalo o nā alakaʻi GMP no ka manawa mua. Ma waena o 1981 a me 1991, ua hoʻonui ʻia ʻo Bachem i kona mana hana, ʻoiai ua piʻi ka nui o nā limahana i 150. Ma 1995, ua hoʻonui ʻia nā mea hana, me ka ʻoihana hoʻomalu maikaʻi, i ka huina o 168,000 sq. ft. (15,600 m2). Ua piʻi ka nui o nā limahana i 190.
Hoʻomaka ka hoʻonui ʻana i nā mākeke non-European me ka hoʻokumu ʻana o Bachem Bioscience, Inc. ma Philadelphia, USA, ma 1987. No ka hoʻoikaika ʻana i kona noho ʻana ma ʻEulopa, ua wehe ʻo Bachem i nā kikowaena kūʻai aku a kūʻai aku ma Germany ma 1988 a ma Palani i ka makahiki 1993. I ka makahiki 1996, ua loaʻa iā ia ka lua o ka mea hana nui o nā peptides, Bachem Kaleponi ma Torrance, USA, me kāna mau lālā ma Germany a me UK.
Hele ʻo Bachem i ka lehulehu ma Iune 18, 1998. Ua helu ʻia nā ʻāpana ma ka Swiss Stock Exchange. Ua loaʻa i ka Pūʻulu ke kūʻai aku o 96 miliona CHF a hoʻohana i 331 poʻe ma ka honua holoʻokoʻa. I ka makahiki 1999, ua loaʻa iā Bachem ka Peninsula Laboratories, Inc., i hoʻokumu ʻia ma San Carlos, Kaleponi, a me kāna ʻoihana ma ʻEnelani, i hoʻohui ʻia me Bachem UK - ʻo ia iho he lālā o California-based Bachem Inc. ma 2000.
ʻO ka loaʻa ʻana o Sochinaz SA, kahi mea hana kūikawā ma Swiss (Vionnaz) o nā mea lāʻau lapaʻau ikaika i ka makahiki 2001, ua hoʻoikaika i ka ʻike o Bachem a hoʻonui hou i kāna mau hana hana. Ua ulu ka poʻo o ka Pūʻulu i kēia manawa i nā limahana 500 a hiki ke kūʻai aku i 141,4 miliona CHF.
No laila ʻo kēia ka papa inoa o nā ʻoihana lāʻau lapaʻau kiʻekiʻe Swiss e pili ana i ke kūʻai aku i kēia makahiki i hala.
Heluhelu hou e pili ana ʻO nā ʻoihana Pharma kiʻekiʻe ma India.